Skip to content

Pregnancy And Liver adenoma Management

Pregnancy And Liver adenoma Management - PALM-study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47417
Enrollment
50
Registered
2011-08-26
Start date
2011-11-01
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver adenoma

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Study groep: Properly Dutch speaking, pregnant patients, 18 years of age or older with a radiologically and/or histologically proven diagnosis of hepatocellular adenoma can be included in the study. Radiological diagnosis of HCA will be based on contrast enhanced magnetic resonance imaging (pre- or postpartum). Lesions must not exceed 5 cm. Informed consent must be signed.

Exclusion criteria

Exclusion criteria: Dementia or impaired mental function that would counter the understanding of giving informed consent.

Design outcomes

Primary

MeasureTime frame
*To investigate the proportion of patients in which HCA growth during pregnancy occurs

Secondary

MeasureTime frame
*To investigate in which trimester of pregnancy growth of HCA occurs; *To investigate the degree of growth of HCA during pregnancy; *To investigate whether there is regression of HCA postpartum; *To investigate the HCA-related interventions during pregnancy; *To investigate the incidence of bleeding of HCA during pregnancy; *To investigate liver-related clinical signs during pregnancy; *To investigate elevated liver enzymes during pregnancy; *To evaluate the quality of life of pregnant patients with HCA; *To investigate whether there is a difference between quality of life of pregnant patients with HCA and pregnant patients with other comorbidity that have an indication for pregnancy care at the obstetrician in secondary care and healthy pregnant patients.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)